Translate Bio Overview

  • Founded
  • 2010
Founded
  • Status
  • Public
  • Employees
  • 122
Employees
  • Stock Symbol
  • TBIO
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $18.36
  • (As of Friday Closing)

Translate Bio General Information

Description

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Contact Information

Website
www.translate.bio
Formerly Known As
RaNA Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 29 Hartwell Avenue
  • Lexington, MA 02421
  • United States
+1 (617) 000-0000

Translate Bio Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Translate Bio Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$18.36 $18.76 $11.91 - $34.64 $1.38B 75.2M 1.01M -$0.28

Translate Bio Financials Summary

In Thousands,
USD 		TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 648,901 761,131 291,136 177,466
Revenue 168,756 138,811 7,804 1,420
EBITDA (7,629) (44,517) (109,047) (101,442)
Net Income (12,983) (53,787) (113,293) (97,395)
Total Assets 890,640 889,936 336,201 287,651
Total Debt 60,688 62,686 12,614 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Translate Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Translate Bio‘s full profile, request access.

Request a free trial

Translate Bio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Translate Bio‘s full profile, request access.

Request a free trial

Translate Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative med
Drug Discovery
Lexington, MA
122 As of 2020
00000
000000000 00000

00000000

at nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserun
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000 000

ore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000 000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Translate Bio Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000000000 Formerly VC-backed Culver City, CA 000 00000 000000000000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
You’re viewing 5 of 28 competitors. Get the full list »

Translate Bio Executive Team (19)

Name Title Board Seat Contact Info
Ronald Renaud Jr. Chief Executive Officer & Board Member
Brendan Smith Chief Financial Officer & Corporate Strategy
Paul Burgess JD Chief Operating Officer, Operations & Secretary, Administration
Richard Wooster Ph.D Chief Scientific Officer
Greg Troiano Chief Manufacturing Officer
You’re viewing 5 of 19 executive team members. Get the full list »

Translate Bio Board Members (17)

Name Representing Role Since
Daniel Lynch Self Chairman & Board Member 000 0000
Daniella Beckman Self Board Member 000 0000
George Demetri MD Translate Bio Board Member 000 0000
Iain Dukes Ph.D Self Board Member 000 0000
Jean-Francois Formela MD Self Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Translate Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Translate Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Translate Bio‘s full profile, request access.

Request a free trial

Translate Bio Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 (000 0000000 04-Jan-2017 000000000 00000 00 00000 Buildings and Property 000000 000000 00.
To view Translate Bio’s complete investments history, request access »